No merit seen in including Paxlovid in Covid treatment: ICMR - Video
Overview
Pfizer's antiviral drug Paxlovid is not going to be included in the national treatment guidelines for Covid-19. Confirmation to this effect was recently made by the Experts from the Indian Council of Medical Research (ICMR) to the daily Economic Times who said that the apex medical authority has not found a compelling reason to include the drug in the national treatment guidelines for Covid-19.
"Members of ICMR's National Task Force on Covid-19 had met last week to discuss the matter but did not find merit in the drug's inclusion in the national treatment guidelines for Covid-19. The current evidence did not merit the inclusion of Paxlovid in the treatment guidelines and the existing guidelines stand valid," Samiran Panda, head of epidemiology and infectious diseases at ICMR, told the Economic Times. Panda also added that the experts are awaiting data from ongoing trials and will review it further as data comes.
For more information, check out the full story on the link below:
Paxlovid Not Be Included In National Treatment Guidelines For COVID-19, Says ICMR
Speakers
